Daptomycin dosing & administration

Silverman JA, Mortin LI, VanPraagh ADG, Li T, Alder J · 2005

Why daptomycin must never be used for pneumonia, and the paper that explains it. Daptomycin failed to meet non-inferiority criteria in a trial for severe community-acquired pneumonia, and showed an odd pattern in animal models — it worked in Staphylococcus aureus haematogenous pneumonia and inhalation anthrax but had no activity against Streptococcus pneumoniae in simple bronchial-alveolar pneumonia. The reason is that pulmonary surfactant inhibits it directly, an effect specific to daptomycin and consistent with its membrane mechanism. The authors call this the first example of organ-specific inhibition of an antibiotic. It is why the FDA label states plainly that daptomycin is not indicated for the treatment of pneumonia [6].

Bland CM, Bookstaver PB, Lu ZK, Dunn BL, Rumley KF · 2014

The statin question, with both arms. A multicentre retrospective study across 13 institutions compared 49 adults receiving a statin alongside daptomycin with 171 receiving daptomycin alone. Myalgias occurred in 3 of 49 (6.1%) on the combination against 5 of 171 (2.9%) on daptomycin alone (p=0.38). CPK above 1,000 U/L occurred in 5 of 49 (10.2%) against 9 of 171 (5.3%) (p=0.32), and 2 of those 5 had myopathy symptoms. Three patients (6.1%) stopped because of CPK elevation with myalgia against 6 (3.5%) in the daptomycin-alone group (p=0.42). CPK and myalgias reversed on stopping daptomycin. Musculoskeletal toxicity was numerically higher on the combination but not statistically so — a study this size could not settle it, which is why the label still asks for more frequent CPK monitoring in patients on a statin [6].

Lee MT, Yang PY, Charron NE, Hsieh MH, Chang YY, Huang HW · 2018

Laboratory work on how daptomycin actually acts on a membrane, and a correction of the textbook picture: the study it builds on disproved the existence of daptomycin ion channels. Using aspirated giant vesicles, the authors found daptomycin causes ion leakage only above a threshold concentration in the membrane, only transiently, and only on first binding — after that the same molecules cease to induce leakage, and the effect cannot be transferred from one membrane to another. Binding is weaker in gel-phase bilayers and weaker again with cholesterol present, which the authors suggest is part of why daptomycin discriminates between bacterial and human cell membranes. This is model-membrane biophysics, not a clinical result.

Iwata S, Koyama H, Murata Y · 2021

An open-label single-arm phase 2 study in 18 Japanese children aged 1 to 17 (14 with complicated skin and soft tissue infection, 4 with bacteraemia), given age-adjusted intravenous daptomycin for 5 to 14 days or 5 to 42 days respectively. Adverse events were reported in 6 of 14 (42.9%) of the skin-infection group and 4 of 4 (100%) of the bacteraemia group, but there were no deaths, no serious adverse events and no discontinuations for adverse events. Among the 8 participants with MRSA, 7 (87.5%) had a favourable clinical response at test of cure. Eighteen children with no control arm — supportive, not decisive.

Samura M, Takada K, Hirose N, Kurata T, Nagumo F, Uchida M, et al. · 2023

The paper that settles the high-dose question, and it cuts both ways. Pooling across four databases, standard dose (4-6 mg/kg) was compared with high dose (above 6 mg/kg) and with 8 mg/kg or more. In complicated bacteraemia and infective endocarditis, treatment success was significantly LOWER on standard dose than on high dose (odds ratio 0.48, 95% CI 0.30-0.76 for complicated bacteraemia; 0.50, 0.30-0.82 for endocarditis) and lower still against the 8 mg/kg or more group (0.38, 0.21-0.69 and 0.30, 0.15-0.60). For osteomyelitis and foreign-body or prosthetic infection, standard dose did not do worse. The cost is measurable: the incidence of elevated CPK was significantly lower on standard dose than on high dose. So high dose buys success in complicated bloodstream infection and endocarditis, and pays for it in muscle enzyme elevation.

U.S. Food and Drug Administration; NorthStar Rx LLC · 2024

Indicated for complicated skin and skin-structure infections in adults and children aged 1 to 17, and for Staphylococcus aureus bloodstream infection in adults (including right-sided infective endocarditis) and in children aged 1 to 17. Three limitations of use matter more than the indications: it is NOT indicated for pneumonia, NOT indicated for LEFT-sided infective endocarditis due to S. aureus, and NOT recommended below one year of age because of effects on muscular, neuromuscular and nervous systems seen in neonatal dogs. Adult dosing is 4 mg/kg every 24 hours for 7-14 days in skin infection and 6 mg/kg every 24 hours for 2-6 weeks in bacteraemia, moving to every 48 hours below a creatinine clearance of 30 mL/min including haemodialysis and CAPD, given after dialysis on dialysis days. Warnings cover anaphylaxis, myopathy and rhabdomyolysis, eosinophilic pneumonia, DRESS, tubulointerstitial nephritis, peripheral neuropathy, Clostridioides difficile diarrhoea, and reduced efficacy in moderate baseline renal impairment. The only contraindication is known hypersensitivity to daptomycin.